Erleada
What Erleada is used for
Erleada is indicated: in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Erleada
- Active substance
- apalutamide
- Disease area
- Prostatic Neoplasms
- Medicine group
- Endocrine therapy
- ATC code
- L02BB05
- Marketing authorisation holder
- Janssen-Cilag International NV
- Authorised in the EU since
- 2019
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Erleada used for?
Erleada is indicated: in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).
What is the active substance in Erleada?
Erleada contains apalutamide.
Who makes Erleada?
The EU marketing authorisation holder is Janssen-Cilag International NV.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU